Protara Therapeutics, Inc. OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
Protara Therapeutics, Inc. (TARA) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of $1.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2026-08-11
- Protara Therapeutics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2026-06-30 was $1.00K.
- Protara Therapeutics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2026-03-31 was -$454.00K, a 621.84% decline year-over-year.
- Protara Therapeutics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2025-12-31 was -$53.00K.
- Protara Therapeutics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2025-09-30 was $66.00K, a 127.59% increase year-over-year.
- Protara Therapeutics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2025 was $88.00K, a 166.67% increase from fiscal 2024.
- Protara Therapeutics, Inc. oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2024 was $33.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00K 10-Q · filed 2026-08-11 | -$453.00K 10-Q · filed 2026-08-11 | -$506.00K derived: sum of 3 quarters · filed 2026-08-11 | -$440.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$454.00K 10-Q · filed 2026-05-13 | -$507.00K derived: sum of 2 quarters · filed 2026-05-13 | -$441.00K derived: sum of 3 quarters · filed 2026-05-13 | -$453.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $13.00K derived: sum of 2 quarters · filed 2026-03-10 | $1.00K derived: sum of 3 quarters · filed 2026-08-11 | $88.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | $66.00K 10-Q · filed 2025-11-10 | $54.00K derived: sum of 2 quarters · filed 2026-08-11 | $141.00K 10-Q · filed 2025-11-10 | $114.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$12.00K 10-Q · filed 2026-08-11 | $75.00K 10-Q · filed 2026-08-11 | $48.00K derived: sum of 3 quarters · filed 2026-08-11 | $77.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $87.00K 10-Q · filed 2026-05-13 | $60.00K derived: sum of 2 quarters · filed 2026-05-13 | $89.00K derived: sum of 3 quarters · filed 2026-05-13 | $90.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $2.00K derived: sum of 2 quarters · filed 2026-03-10 | $3.00K derived: sum of 3 quarters · filed 2026-03-10 | $33.00K 10-K · filed 2026-03-10 |
| 2024-09-30 | $29.00K 10-Q · filed 2025-11-10 | $30.00K derived: sum of 2 quarters · filed 2025-11-10 | $60.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $1.00K 10-Q · filed 2025-08-11 | $31.00K 10-Q · filed 2025-08-11 | ||
| 2023-09-30 | $171.00K 10-Q · filed 2024-11-12 | $304.00K derived: sum of 2 quarters · filed 2024-11-12 | $523.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $133.00K 10-Q · filed 2024-08-06 | $352.00K 10-Q · filed 2024-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |